Subset of a group that forms a group itself
POPULARITY
5 episodes with subgroups
3 episodes with subgroups
2 episodes with subgroups
2 episodes with subgroups
2 episodes with subgroups
2 episodes with subgroups
2 episodes with subgroups
2 episodes with subgroups
2 episodes with subgroups
In this JCO Article Insights episode, Rohit Singh provides a summary on "First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data", by Long et al, published in the November issue of the Journal of Clinical Oncology. The article provides insights into the use of the two dual immune checkpoint inhibitor regimens in patients with untreated advanced melanoma. TRANSCRIPT Rohit Singh: Hello and welcome to JCO Article Insights. I'm your host Rohit Singh, Assistant Professor at the University of Vermont Cancer Center and today we'll be discussing the article “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trials,” authored by Dr. Georgina Long from the Melanoma Institute of Australia and her colleagues. So as we know, nivolumab plus relatlimab and nivo plus ipi, I'm going to refer to as ipi-nivo moving forward, are dual immune checkpoint inhibitors regimens that are approved for treating patients with advanced melanoma based on the phase 2 and 3 RELATIVITY-047 and phase 3 CheckMate 067 trials respectively. Nivo plus relatlimab is the only dual PD-1 and LAG-3 inhibitor regimen approved for treating patients with advanced melanoma and relatlimab is the first in class human IgG4 LAG-3 blocking antibody. Ipi plus nivo is a dual PD-1 and CTLA-4 inhibitor regimen. So this paper basically is an indirect treatment comparison using a patient level database from these trials and this pretty much was conducted because of the absence of head to head trials looking at different regimens in advanced melanoma in first line setting. In this trial, the authors tried to compare these two trials. However, it's always hard to compare two different trials and we usually don't do cross trial comparisons. The problem is that the groups might be different to begin with. For example, one group might have younger patients, healthier patients, while the other might have older or sicker. These differences can make it hard to tell if the treatment caused improvement or if the groups were different to begin with. In this trial, researchers use inverse probability of treatment weighting to adjust the baseline differences between the two patient groups or between these two trials. Inverse probability of treatment weighting is a method used in research to help make a fair comparison between two groups when studying how a treatment intervention works. Basically, IPTW helps level the playing field between the two groups or like two trials for this paper. So, it calculates the likelihood of receiving a treatment. For each person, for each patient, researchers estimate the chance they would have gotten the treatment based on their characteristics like age, health, condition, their baseline staging, and based on that they create weights. People who are less likely to get the treatment but did are given more weight, and those who are very likely to get the treatment are given less weight. The same is done for the group that didn't get the treatment, and then they rebalance the groups. By applying these weights the group becomes more similar in their characteristics as if everyone had an equal chance of getting the treatment. This way, IPTW helps researchers focus on the effect of treatment itself and other differences between the groups. It's like adjusting the scales to make sure you are comparing apples to apples. The key outcomes the authors are looking at in this one was progression free survivals, overall survival, confirmed objective response rate, melanoma specific survival, and treatment related adverse events. Looking at the results of this cross comparison trial, first looking at the PFS or progression free survival, both regimens ipi plus nivo and nivo plus relatlimab, showed similar PFS. At 36 months, PFS was 36% in nivo-relatlimab versus 39% in the ipi-nivo regimen with a hazard ratio of 1.08 indicating no significant differences. Looking at the overall survival at 36 months, overall survival was 57% in both the treatment regimens with a hazard ratio of 0.14, again, indicating no significant differences. Now looking at another confirmed objective response rate, confirmed objective rates were similar between both treatment regimens after weighting, 48% versus 50% with an odds ratio of 0.91 suggesting comparable response rates between the two regimens. Looking at melanoma specific survival at 36 months it was 65% versus 62%. Both treatments had similar melanoma specific survival with a hazard ratio 0.86. An interesting thing in these results was subgroup analysis. Subgroups showed larger numerical differences in efficacy which favored ipi-nivo over nivo-relatlimab that included acral melanoma with a hazard ratio of 1.42 and OS with a hazard ratio of 1.72 in favor of ipi-nivo. Similarly for BRAF mutant melanoma, it showed a confirmed objective response rate with odds ratio 1.54 and same applied to mucosal melanoma with odds ratio of 1.59 and patients who have high LDH more than two times upper level limit. Looking at the safety and adverse side effects, nivolumab plus relatlimab had fewer grade 3 or 4 treatment related adverse effect which is 23% versus 61% and fewer any grade treatment related adverse events leading to discontinuation which was 17% versus 41%, which means 41% of the patients in the ipi-nivo arm lead to discontinuation. However, I would like to add to that that ipi-nivo was conducted much earlier and at that time we were still kind of assessing and trying to understand the immunity adverse effects, how to manage them, which probably could have made discontinuation more common compared to a nivo-relatlimab trial. By that time we definitely had much more experience dealing with immunity adverse effects.A couple of things mentionable in this, notable rates of hepatic and GI grade 3 or 4 treatment adverse events were lower in nivo plus relatlimab than with ipi-nivo, although the onset of any grade endocrine GI hepatic or skin related treatment related adverse events occurred most frequently in both treatment arms and in less than three months from randomization. So looking at all this data and looking at all this, it definitely seems like both the trials are very comparable in terms of efficacy, though nivo plus relatlimab seems to have a better safety profile. This trial does have some strengths. It does use the patient level data from two large well conducted trials allowing for a robust comparison and inverse weighting which would definitely better help balance baseline characteristics, enhancing the reliability of the results, and it does lead to comprehensive assessment of both efficacy and safety outcomes, and provides a holistic view of the treatments. Given all this, definitely the fact that it's a cross comparison trial which leads to a big limitation, as I already mentioned, like definitely two trials, it's hard to compare two trials which can have its own inherited biases. So it has some differences in trial design, conduct and follow up times. Small size subgroup analysis definitely limits the ability to draw definite conclusions from those groups. There's definitely some inherent uncertainty with direct head to head cross comparison trials. Looking at the future direction I would take from this trial, if we can have a direct head to head trial because both of the treatments are proven first line setting, it will be comparing these two regimen that can definitely provide more definite evidence and further research is needed to explore the efficacy of these regimens in specific subgroups. As I mentioned in this, some subgroups showed increased benefit in the ipi-nivo regimen, however, they were very small sample size so we need more research exploring those subgroups. One other part in both these trials, patients with active brain mets were excluded. However, there's a phase 2 trial looking at ipi-nivo in active brain mets patients. So I think assessing patients with active brain mets moving forward is also a crucial part looking at, because often, patients with advanced melanoma develop brain mets. It does lead to some unanswered questions like long term survival and quality of life. How do these regimens compare in terms of long term survival and quality of life? While the study provides data on PFS and OS, long term survival and quality of life metrics are essential for understanding the full impact of these treatments. Optimal sequencing strategies: what are the optimal sequence strategies for these patients who progress on one regimen? There is data suggesting that patients may respond to alternative regimens after progression, but more research is needed to establish the best treatment sequence. And real world performance: how do these treatments perform in real world settings outside of clinical trials? Real world data can provide insight into the effectiveness and safety of these regimens in a broader patient population. So, in summary, nivo plus relatlimab offers similar efficacy to nivolumab plus ipilimumab but a significantly improved safety profile, making it the potentially preferable option for patients with untreated advanced melanoma. However, results should be interpreted with caution due to limitations of cross trial analysis for certain subgroups like acral melanoma, mucosal melanoma, BRAF mutant melanoma, and patients with high LDH more than two times off upper normal limit. The trial showed that there's a trend definitely with ipi-nivo may be more beneficial. Also, today data on the use of nivolumab plus relatlimab in active brain mets has not been reported. Based on these existing data, ipi-nivo remains a standard immunotherapy for patients with active brain mets. Further research, including direct head to head trials is needed to confirm these findings and explore optimal treatment strategies. Thank you for tuning into today's episode. We hope this detailed summary of the study comparing Nivolumab Plus Relatlimab and Nivolumab Plus Ipilimumab in advanced melanoma has been informative. This is Rohit Singh. Thank you again for listening to JCO Article Insights. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.
Better Edge : A Northwestern Medicine podcast for physicians
Nilay S. Shah, MD, MPH, explores how social factors and disparities affect cardiovascular health in Asian American subgroups. He emphasizes the need to understand and address these factors in patient care.
In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Banerjee and Raje spoke in the context of prior advisories from the FDA on the potential development of secondary T-cell malignancies in patients who receive CAR T-cell therapy for hematologic cancers. Specifically, the agency required a boxed warning for secondary T-cell malignancy risks for BCMA- or CD19-targeting therapies in April 2024.1 The conversation also touched upon reports of secondary malignancies in cases and trials such as CARTITUDE-1 (NCT04181827), in which second primary cancers were highlighted in 9 patients who received treatment with ciltacabtagene autoleucel (Carvykti).2 Considering these reports and warnings, Banerjee and Raje emphasized shared treatment decision-making with patients after assessing the risks and benefits of CAR T-cell therapy compared with other agents like bispecific antibodies. They also reviewed optimal strategies for monitoring and referring patients based on the incidence of certain toxicities. “[Treatment with] CAR T cells requires planning, and we need to have good control of the disease. We need to have 4 to 6 weeks of a lead time to get these effective treatments to our patients, so early referral is a good idea,” Raje said. “[For example], if you see chronic diarrhea in someone that is way out of the window of what you would expect, referring back to the CAR T-cell center is important so that we don't miss some of these toxicities.” References FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. News release. FDA. April 18, 2024. Accessed August 22, 2024. https://tinyurl.com/5n8pm5ca San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379
In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Banerjee and Raje spoke in the context of prior advisories from the FDA on the potential development of secondary T-cell malignancies in patients who receive CAR T-cell therapy for hematologic cancers. Specifically, the agency required a boxed warning for secondary T-cell malignancy risks for BCMA- or CD19-targeting therapies in April 2024.1 The conversation also touched upon reports of secondary malignancies in cases and trials such as CARTITUDE-1 (NCT04181827), in which second primary cancers were highlighted in 9 patients who received treatment with ciltacabtagene autoleucel (Carvykti).2 Considering these reports and warnings, Banerjee and Raje emphasized shared treatment decision-making with patients after assessing the risks and benefits of CAR T-cell therapy compared with other agents like bispecific antibodies. They also reviewed optimal strategies for monitoring and referring patients based on the incidence of certain toxicities. “[Treatment with] CAR T cells requires planning, and we need to have good control of the disease. We need to have 4 to 6 weeks of a lead time to get these effective treatments to our patients, so early referral is a good idea,” Raje said. “[For example], if you see chronic diarrhea in someone that is way out of the window of what you would expect, referring back to the CAR T-cell center is important so that we don't miss some of these toxicities.” References 1. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. News release. FDA. April 18, 2024. Accessed August 22, 2024. https://tinyurl.com/5n8pm5ca 2. San-Miguel J, Dhakal B, Yong K, et al. CIlta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379
Commentary by Dr. Candice Silversides
At the 2024 European Hematology Association (EHA) Congress, CancerNetwork® spoke with a variety of experts in the hematologic oncology space about optimizing outcomes across different patient populations and subgroups based on updated research they presented at the meeting. Manali Kamdar, MD, an associate professor of medicine-hematology and clinical director of Lymphoma Services at the University of Colorado Anschutz Medical Campus, in Colorado, spoke about data from the phase 1 TRANSCEND NHL 001 trial (NCT02631044) supporting the use of lisocabtagene maraleucel (liso-cel; Breyanzi) in earlier lines of therapy for patients with relapsed/refractory mantle cell lymphoma (MCL).1 Specifically, Kamdar highlighted how research should continue to focus on the potential utility of liso-cel in MCL subgroups such as those with TP53 mutations or blastoid morphology. Additionally, she stated that liso-cel may need to be further tested in earlier lines of therapy for patients with diffuse large B-cell lymphoma, including those with double-hit lymphoma. Michael R. Grunwald, MD, chief of the Leukemia Division and director of the Transplantation and Cellular Therapy Program at Atrium Health's Levine Cancer Institute, in North Carolina, discussed findings from the Prospective Observational Study of Patients With Polycythemia Vera (PV) in US Clinical Practices Trial (REVEAL) exploring risk factors for disease progression in patients with polycythemia vera (PV).2 According to Grunwald, a history of thromboembolic events, elevated white blood cell counts, and higher variant allele frequencies may contribute to a patient's likelihood of experiencing progression to myelofibrosis or acute myeloid leukemia (AML). Additionally, he highlighted ongoing research into the potential molecular factors that may prognosticate disease transformation in PV among a small cohort of patients enrolled on the REVEAL trial.3 Harry P. Erba, MD, PhD, a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy and the director of the Leukemia Program and Phase I Development in Hematologic Malignancies at Duke Cancer Institute, in North Carolina, discussed the clinical implications of data from the phase 3 QuANTUM-First study (NCT02668653).4 Specifically, findings demonstrated that continuation therapy with quizartinib (Vanflyta) elicited a more pronounced survival benefit vs placebo in patients with newly diagnosed FLT3-ITD–positive AML who did not undergo allogeneic hematopoietic stem cell transplant (allo-HSCT). However, Erba noted that survival outcomes were not significantly different in the quizartinib and placebo arms among patients who received allo-HSCT. References 1. Palomba ML, Siddiqi T, Gordon LI, et al. Subgroup analyses in patients with R/R MCL treated with lisocabtagene maraleucel by prior lines of therapy and response to Bruton tyrosine kinase inhibitor from the TRANSCEND NHL 001 MCL cohort. Presented at the European Hematology Association (EHA) 2024 Congress; Madrid, Spain; June 13-16, 2024. P1126. 2. Grunwald M, Zwicker J, Gerds A, et al. A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV) enrolled in REVEAL. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract P1047. 3. Crowgey E, Timmers C, Xue Z, et al. Analysis of molecular mechanisms and predictive biomarkers of disease transformation in polycythemia vera. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S217. 4. Sekeres MA, Erba H, Montesinos P, et al. QuANTUM-First: efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S142.
Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
Drs. Eugene Yang and Amber Tang discuss social determinants and impact on cardiovascular risk factors among disaggregated Asian subgroups.
In this episode, Zange lays out the ups and downs of wildly popular boy group, EXO. Lawsuits! Olympics! Military service! This episode has all this and more. Playlist for this episode: https://open.spotify.com/playlist/4MwDcnxkbxzbvyFDUuOj8y?si=6d990e0329954523
DOI: 10.13056/acamh.26603 In this Papers Podcast, Dr. Si-Jing Chen discusses her JCPP paper ‘Subtyping at-risk adolescents for predicting response toward insomnia prevention program' (https://doi.org/10.1111/jcpp.13904). Si-Jing is the first author of the paper. There is an overview of the paper, methodology, key findings, and implications for practice. Discussion points include: Insomnia prevalence and impact in adolescences. Insight into the brief cognitive-behavioural prevention insomnia programme. Why the cognitive-behavioural sleep intervention was predominantly more effective for anxiety than depression. Implications of findings for CAMH professionals, and how the findings can be translated into practice. In this series, we speak to authors of papers published in one of ACAMH's three journals. These are The Journal of Child Psychology and Psychiatry (JCPP); The Child and Adolescent Mental Health (CAMH) journal; and JCPP Advances.
Richard Borcherds is a mathematician and professor at University of California Berkeley known for his work on lattices, group theory, and infinite-dimensional algebras. His numerous accolades include being awarded the Fields Medal in 1998 and being elected a fellow of the American Mathematical Society and the National Academy of Sciences. Patreon (bonus materials + video chat): https://www.patreon.com/timothynguyen In this episode, Richard and I give an overview of Richard's most famous result: his proof of the Monstrous Moonshine conjecture relating the monster group on the one hand and modular forms on the other. A remarkable feature of the proof is that it involves vertex algebras inspired from elements of string theory. Some familiarity with group theory and representation theory are assumed in our discussion. I. Introduction 00:25: Biography 02:51 : Success in mathematics 04:04 : Monstrous Moonshine overview and John Conway 09:44 : Technical overview II. Group Theory 11:31 : Classification of finite-simple groups + history of the monster group 18:03 : Conway groups + Leech lattice 22:13 : Why was the monster conjectured to exist + more history 28:43 : Centralizers and involutions 32:37: Griess algebra III. Modular Forms 36:42 : Definitions 40:06 : The elliptic modular function 48:58 : Subgroups of SL_2(Z) IV. Monstrous Moonshine Conjecture Statement 57:17: Representations of the monster 59:22 : Hauptmoduls 1:03:50 : Statement of the conjecture 1:07:06 : Atkin-Fong-Smith's first proof 1:09:34 : Frenkel-Lepowski-Meurman's work + significance of Borcherd's proof V. Sketch of Proof 1:14:47: Vertex algebra and monster Lie algebra 1:21:02 : No ghost theorem from string theory 1:25:24 : What's special about dimension 26? 1:28:33 : Monster Lie algebra details 1:32:30 : Dynkin diagrams and Kac-Moody algebras 1:43:21 : Simple roots and an obscure identity 1:45:13: Weyl denominator formula, Vandermonde identity 1:52:14 : Chasing down where modular forms got smuggled in 1:55:03 : Final calculations VI. Epilogue 1:57:53 : Your most proud result? 2:00:47 : Monstrous moonshine for other sporadic groups? 2:02:28 : Connections to other fields. Witten and black holes and mock modular forms. Further reading: V Tatitschef. A short introduction to Monstrous Moonshine. https://arxiv.org/pdf/1902.03118.pdf Twitter: @iamtimnguyen Webpage: http://www.timothynguyen.org
Host Dr. Christopher O'Connor invites Drs. Scott Solomon, William Abraham, JoAnn Lindenfeld, Brian Claggett, Mona Fiuzat, and Mitchell Psotka to continue discussion of the importance of subgroups in heart failure clinical trials. How can we analyze subgroups and determine the differences between subgroups and special populations?
A new study examines the health utility of patients at 60 days after dialysis-requiring acute kidney injury and identifies 3 subgroups of AKI survivors with distinct health utility profiles.
Host Dr. Christopher O'Connor invites Drs. Javed Butler, Mariell Jessup, and Mitchell Psotka to discuss the importance of subgroups in heart failure clinical trials. How do we appropriately define subgroups? Which groups should be included as standard practice in HF trials?
In this episode, CardioNerds Dr. Daniel Ambinder, Dr. Giselle Suero Abreu, and Dr. Saahil Jumkhawala discuss thromboembolic disease in cardio-oncology with faculty expert Dr. Joshua Levenson, the Associate Program Director of the cardiology fellowship and an Assistant Professor of Medicine at the University of Pittsburg School of Medicine. Venous (VTE) and arterial thromboembolic (ATE) events are precipitants of morbidity and mortality in patients with cancer. Here, we discuss the pathophysiology of thromboembolism, risk factors and epidemiology for ATE and VTE, the role of risk prediction and patient stratification, and the approach to treatment for and prophylaxis of thromboembolic events with anticoagulation. Show notes were drafted by Dr. Saahil Jumkhawala and episode audio was edited by CardioNerds Intern Dr. Tina Reddy. This episode is supported by a grant from Pfizer Inc. This CardioNerds Cardio-Oncology series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Giselle Suero Abreu, Dr. Dinu Balanescu, and Dr. Teodora Donisan. CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Thromboembolic Disease in Cardio-oncology Patients with cancer are at higher risk of developing both arterial and venous thromboembolic events compared to the general population. Certain cancer subtypes are associated with a relatively higher risk of developing thromboembolic complications. Anticoagulation type and duration should be dependent on patient characteristics and risk factors, with shared decision-making between the patient and their providers. Subgroups of patients may benefit from more aggressive management of their atherosclerotic cardiovascular risk factors while being treated for cancer to reduce the risk of thromboembolic complications. Show notes - Thromboembolic Disease in Cardio-oncology What are the incidence and main manifestations of thromboembolic events (venous and arterial) in patients with active malignancy? Approximately 10% of outpatients with active cancer have venous thromboembolic events, many of which are asymptomatic. Clinically relevant VTEs are predominantly deep venous thrombosis (DVTs) with pain and/or swelling of the involved extremities or pulmonary emboli (PEs) resulting in chest pain and/or shortness of breath. VTE is the number one preventable cause of death for all hospitalized patients, and the ability to prevent and treat these events is crucial, particularly in high-risk populations such as patients with cancer. Are there any high-risk associations with specific cancer subtypes? Patients with metastatic disease and those receiving chemotherapy are more likely to develop arterial or venous thromboembolic events. Patients with acute myelogenous leukemia (AML) and thrombocytopenic patients are at the lowest risk for thromboembolic events. Multiple myeloma patients on medication such as proteasome inhibitors or lenalidomide appear at particular risk. Patients with localized, early-stage cancers such as breast, prostate, and melanoma are also at lower risk. What are the main risk factors to identify patients at a higher risk of developing thrombotic complications? Patients with a sedentary lifestyle, deconditioning, and undergoing active treatment with chemotherapy are at the highest risk of developing DVT or PE. How should we approach choosing the optimal type and duration of anticoagulation for acute pulmonary embolism (PE) in the setting of malignancy? This remains an area of active research. Historically, patients would receive systemic anticoagulation with heparin followed by warfarin.
Young Men, Republican Women, And More: Targeting Some Key Subgroups by Zach Wulderk at Faunalytics.org Original post https://faunalytics.org/comparing-selected-u-s-subgroups-openness-to-pro-animal-actions/ Faunalytics is a non-profit organization providing animal advocates with data to understand how people think about and respond to advocacy, and the best strategies to inspire change for animals. They empower advocates with access to research, analysis, strategies, and messages that maximize their effectiveness to reduce animal suffering. Their online research library is free and has summaries of over 4,000 peer-reviewed research articles, public opinion surveys, and blog posts offering deep analysis on every animal issue you can think of. It's the world's biggest collection of opinion and behavior research about animal issues, and it's presented with an emphasis on effectiveness, readability, and useability. Sign up for their email alerts and get weekly or monthly updates on the latest research. How to support the podcast: Share with others. Recommend the podcast on your social media. Follow/subscribe to the show wherever you listen. Buy some vegan/plant based merch: https://www.plantbasedbriefing.com/shop Follow Plant Based Briefing on social media: Twitter: @PlantBasedBrief YouTube: YouTube.com/PlantBasedBriefing Facebook: Facebook.com/PlantBasedBriefing LinkedIn: Plant Based Briefing Podcast Instagram: @PlantBasedBriefing #vegan #plantbased #plantbasedbriefing #animaladvocacy #veganoutreach #effectiveadvocacy
We listen to a clip from Victor Davis Hanson's YouTube and talk about the organizational dynamics in the country. Why have we come to such tribalism and empowering of the subgroups? What do we need to do to restore the parent group that created the mission and vision of this country? Mike and Julie discuss the variables they think might be related to the problem of subgroup tribalism.Our video:https://youtu.be/6c0gcvOF_RsFollow Us:YouTubeTwitterFacebookTumblrAll audio & videos edited by: Jay Prescott Videography
Commentary by Dr Nathan Wong
In this edition of Null and Noteworthy, researchers upend early interventions and diagnostic boundaries.
In this edition of Null and Noteworthy, researchers upend early interventions and diagnostic boundaries.
In today's world we face pain and illness all around us. We face the risk of different diseases that can impact our lives. Now, more than ever, taking care of ourselves is essential. Through God's guidance, we can find healing and protection from disease for our mind, body, and spirit. He has given us the ability to become healthy and stay strong through faith, prevention, and nature's medicine.[1]God's Word and natural medicine can help us tap into this God-given ability to heal our mind, body, and spirit. In this episode of the Revelations Podcast, Dr. George Kramer shares his experience using natural medicine, prayer and the Word of God. We dig into the roots of medicine and talk about the role of spiritual medicine in illness and healing and dive into what Scripture says about our health and treatment. Dr. George also shares his advice to help us start caring for ourselves with natural and regenerative medicine.Join us in this conversation to learn more about what the Holy Bible says about health and God's role as our healer.Here are three reasons why you should listen to this episode:Discover how to use nature's medicine to heal and prevent illnesses.Understand more about God's Word as we dive into the scriptures about health and healing.Take an active role in your health with the simple things you can do to care for yourself.ResourcesMore from the Revelations Podcast: Website | Instagram | Apple PodcastLearn about Dr. George Kramer and his practice on his websiteHidden Bible Health Secrets by Reginald Cherry, M.D.Bible Verses:1 John 1:9Proverbs 17:22Exodus 15:26Proverbs 4: 20-22Proverbs 14:30Jeremiah 17:14Deuteronomy 28Deuteronomy 30:193 John 1:2This Episode is brought to you by Advanced Medicine AlternativesGet back to the active life you love through natural & regenerative musculoskeletal healing: https://www.georgekramermd.com/Episode Highlights[03:35] A Healthy Spirit, Mind, and BodyDisease is unease, strife, and struggle. The Scripture says that a crushed spirit dries up the bone. Dr. Kramer explains how a crushed spirit can dry the bone marrow and affect the immune system.There needs to be a holistic approach to health. Our spiritual and emotional health affects our physical body.The Bible has directions on how to treat our body, mind, and spirit. The body is the temple of the Holy Spirit; we need to take care of it.Taking care of your body can mean a healthy diet and avoiding toxins in your mind, body, and spirit.[08:06] The History of MedicineMedical school started in Europe in the 15th or 16th century. Hippocrates is the Father of Medicine. He separated medicine from philosophy, but still called on gods for healing.During the 19th and 20th centuries, Western medicine separated God from medicine.We've recently begun to look at the spiritual roots of illnesses.For Israelites and Hebrew, healing was in the hands of God. Doctors are helpers who administer treatment while God heals.[12:41] Choosing Nature's MedicineThere were already different forms of natural healing in early medicine. Different civilizations used nature's medicine: plants, herbs, and diets.Natural medicine or naturopathy doctors use natural techniques, diets, and supplements to encourage natural healing.While Western medicine has many techniques and medicines that are lifesaving, simply taking care of oneself shouldn't be excluded.The drug industry has taken over the country10.George: “[Pills are] adulterating your body's function rather than stimulating to heal itself, which is a natural medicine way. And God commands us to take care of ourselves naturally.”Unfortunately, drugs are often advertised and encouraged in the U.S. Pharmaceutical medicines have many side effects that might lead to more sickness.[20:00] Preventative MedicineNowadays, preventative medicine has become a specialty. Unfortunately, it still focuses more on pharmaceuticals rather than lifestyle changes.Only a few doctors are educated about this and don't have the time to educate others as well.People often expect prescriptions for treatment. People prefer pills to get better right away instead of changing their lifestyles to prevent disease.It's best to talk to a doctor to find out what we can best do for ourselves. A naturopath consultant can advise on ways to lessen the number of drugs we might need to take.We must actively choose and try to use nature's medicine. A healthy life is worth investing our time, money, and energy in.[23:15] God's Words of HealingRaegan shares how she prefers working with a Christian doctor who understands God.There was a time when she had an atheist physician, and they prayed together for him. God may want us to share Jesus with others who are helping us.The Word of God can help us understand what, why, and how we can heal.God's words are life and healing.[26:19] Heal the Mind to Heal the BodyOur psychological and emotional state can affect the body. Envy, jealousy, bitterness, unforgiveness, trauma, and woundedness can lead to illness. These emotions can be the root of disease.We must stay healthy and care for ourselves physically, emotionally, and mentally. We can do this by knowing the Word, getting social support, and working on our psychological wounds to allow healing.[30:08] God's Paths for HealingIn the Old Testament, God asks for our obedience for His healing and protection from disease. We have a responsibility to understand how God wants us to live.Reagan: “We can live in freedom in that, but also know that we are living in spirit and truth and following the spirit and how he wants us to live. And that brings blessing and that brings healing.”God can provide healing in many different ways. We can use the natural things God gave us and follow practices from the Old Testament to stay healthy.Some Christians who pray for healing receive it, while others can take a slower healing path. God calls on us to take an active role in our healing.In the Bible, Jesus doesn't always heal people right away. He uses natural things and instructs them on treating and caring for themselves.[35:53] Simple Ways to Help OurselvesGod has taught George about healing and taking care of people. He has been able to see the miracle of people's recoveries.One simple way we can help ourselves is by taking Vitamin D supplements. Supplements can help prevent different diseases and support our various organ systems.Low Vitamin D levels can even cause some chronic pain. We need optimal nutrition.It's essential to do everything we can to get what we want. We can't just rely on prayer.[43:44] Different Types of MedicinesTraditional Western medicine or allopathic medicine is disease-oriented. It focuses on identifying the disease before treating it.Natural medicine or naturopathy looks at the balance in the person. It aims to correct the imbalance and optimize the body to heal itself naturally.George: “Our bodies are designed by God to heal if given the right tools and the right situation and the right environment and support.”Alternative medicine includes different techniques from various cultures and traditions. Subgroups include acupuncture, reiki healing, and shamanism.Integrative medicine integrates the different types of medicine. Vitamins, meditation, and others can support modern medical treatment.George uses more natural musculoskeletal medicine to stimulate the body for long-term healing. [49:23] How to Choose LifeGod tells us to choose life. Jesus came down on Earth so that we live our lives fully.The first step is to listen to God's Word and choose to follow Him.The second thing is to learn how to treat our bodies as the temple of the Holy Spirit. We must care for our heart, mind, body, and spirit.It can be a long process. We need to put in the effort and stay healthy continuously. We can only expect progress if we act.Disease can be caused by getting too much of what we don't need and not enough of what we do need.[53:35] Integrating Prayer in Medical PracticeIn the Scripture, John prays for his friends to enjoy good health and for the soul to get along well.Many people have good health but don't enjoy it. They don't realize what they have until they lose it.George encourages those with good health to enjoy their good health. He prays with them if they want to. Prayer gives glory to God and calls upon His healing. It also encourages people to pray for themselves and can awaken their faith.About Dr. George KramerDr. George Kramer is a doctor practicing musculoskeletal medicine and is board certified in physical medicine, rehabilitation, and pain medicine. He has been practicing medicine since 1985 and helps his patients return to an active lifestyle. Dr. Kramer uses natural regenerative medicine to tap into the body's God-given healing ability.To learn more about Dr. Georfe Kramer's practice, visit his website.Enjoyed this Episode?If you did, subscribe and share it with your friends!Post a review and share it! If you enjoyed tuning in, then leave us a review. You can also share this with your friends and family. This episode will teach you about how nature's medicine is a blessing from God.Have any questions? You can connect with me on Instagram.Thank you for tuning in! For more updates, tune in on Apple Podcasts.kw: nature's medicinemeta: Medical knowledge today focuses on drugs and ignores nature's medicine: holistic healing, a healthy lifestyle, and the spirit.
Faulty mTOR signaling, implicated in syndromic forms of autism, also hinders cells grown from people with idiopathic autism or autism-linked deletions on chromosome 16. The post Autism subgroups converge on cell growth pathway appeared first on Spectrum | Autism Research News.
Faulty mTOR signaling, implicated in syndromic forms of autism, also hinders cells grown from people with idiopathic autism or autism-linked deletions on chromosome 16.
Faulty mTOR signaling, implicated in syndromic forms of autism, also hinders cells grown from people with idiopathic autism or autism-linked deletions on chromosome 16.
Series: Ears to HearService: Ears to HearType: Ears to HearSpeaker: John HinesOn this week's episode, we're thinking about the pros and cons of classes and subgroups in the church setting. Thanks for listening.
https://psychiatry.dev/wp-content/uploads/speaker/post-10335.mp3?cb=1665725001.mp3 Playback speed: 0.8x 1x 1.3x 1.6x 2x Download: The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis – Stefan Leucht et al.Full EntryThe response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis –
Had a lovely chat with Shawn Hanlon who is a PhD candidate about his relatively new paper exploring patient features and clinical characteristics and how they may define certain subgroups of Achilles tendinopathy . Lots more to learn in this field and this is early work, but we discuss some of the juicy potential clinical implications. Hope you enjoy! And here is the link to the paper and also the 1/ Hanlon, S.L., Pohlig, R.T. and Silbernagel, K.G., 2021. Beyond the diagnosis: Using patient characteristics and domains of tendon health to identify latent subgroups of Achilles tendinopathy. journal of orthopaedic & sports physical therapy, 51(9), pp.440-448. 2/ And this is the bumper issue of JOSPT from 2015 that is all about tendinopathy: journal of orthopaedic & sports physical therapy, 45(11) See omnystudio.com/listener for privacy information.
Had a lovely chat with Shawn Hanlon who is a PhD candidate about his relatively new paper exploring patient features and clinical characteristics and how they may define certain subgroups of Achilles tendinopathy . Lots more to learn in this field and this is early work, but we discuss some of the juicy potential clinical implications. Hope you enjoy! And here is the link to the paper and also the 1/ Hanlon, S.L., Pohlig, R.T. and Silbernagel, K.G., 2021. Beyond the diagnosis: Using patient characteristics and domains of tendon health to identify latent subgroups of Achilles tendinopathy. journal of orthopaedic & sports physical therapy, 51(9), pp.440-448. 2/ And this is the bumper issue of JOSPT from 2015 that is all about tendinopathy: journal of orthopaedic & sports physical therapy, 45(11) See omnystudio.com/listener for privacy information.
Had a lovely chat with Shawn Hanlon who is a PhD candidate about his relatively new paper exploring patient features and clinical characteristics and how they may define certain subgroups of Achilles tendinopathy . Lots more to learn in this field and this is early work, but we discuss some of the juicy potential clinical implications. Hope you enjoy! And here is the link to the paper and also the 1/ Hanlon, S.L., Pohlig, R.T. and Silbernagel, K.G., 2021. Beyond the diagnosis: Using patient characteristics and domains of tendon health to identify latent subgroups of Achilles tendinopathy. journal of orthopaedic & sports physical therapy, 51(9), pp.440-448. 2/ And this is the bumper issue of JOSPT from 2015 that is all about tendinopathy: journal of orthopaedic & sports physical therapy, 45(11) See omnystudio.com/listener for privacy information.
A graduate student from the University of Wisconsin–Madison is pushing for the disaggregation of data in research to better understand how individuals from different ethnic subgroups are represented as research participants and as researchers. Kao Lee Yang began writing and discussing the topic after the Howard Hughes Medical Institute's Gilliam Fellowship for Advanced Study rejected her application for not meeting their racial and ethnic underrepresentation criteria, despite often being the only Hmong American scientist in many research spaces. Yang joins the podcast to discuss her opinion piece for STAT News, the problems with using aggregated data, and how the push to study individual ethnic groups could improve Alzheimer's disease research. Guest: Kao Lee Yang, MPA/PhD candidate in the Neuroscience and Public Policy Program and Bendlin Laboratory, University of Wisconsin–Madison Episode Topics 6:12 Why is combining all Asian people into one category detrimental? What is improved when this population is broken down by specific heritages and ethnicities? 8:40 How did people respond to your initial article in STAT News? 9:30 Why do you think it's important to look at the individual ethnic groups within research? 11:17 How does the problem of aggregating data on Asian Americans impact the field of Alzheimer's disease research? Show Notes Read Yang's opinion piece, “I'm almost always the only Hmong American scientist in the room. Yet I was told I come from a group overrepresented in STEM,” on STAT News' website. Read Yang's correspondence, “Disaggregate data on Asian Americans — for science and scientists,” on Nature's website. To learn about more Hmong researchers and scientists like Kao Lee Yang, follow the Twitter account she recently launched, @HmongInBioSci. Read about Alzheimer's disease research in the Bendlin Lab.
In this episode of Ventures, my guest Jesse Bryan (https://twitter.com/JesseBryan) and I continue our conversation from episode 89 to discuss multiple aspects of NFTs and NFT clubs. We talk about the history of NFTs, the differences between Moonbirds, Crypto Punks and Bored Ape Yacht Club, the important nuances of intellectual property ownership and licensing, airdrops, community, “staking” of NFTs, cybersecurity, and thoroughly evaluating a team and their roadmap before deciding where to spend your time and money. Visit https://satchel.works/@wclittle/ventures-episode-94 for detailed notes and links to resources (videos, articles, etc…) mentioned. You can watch this episode via video here. 1:54 - Tee up for the episode, recap of Part 1 (Ep 89), storytelling in organizations, introduction to the world of NFTs.2:40 - Quick background on Jesse and his introduction take on NFTs // He believes the next billion dollar brands are going to come out of the NFT space.3:45 - Background on Ethereum, ICOs originally, but NFTs started in 2017…Punks, Kitties, and then Apes didn't launch until April 2021. 5:19 - History of NFTs from Jesse's brand-building perspective9:53 - What the Bored Apes did that the Crypto Punks didn't (e.g. IP ownership)12:00 - Tweet, minting a bored ape 1 year ago turned into the best investment of all time. https://twitter.com/JulianKlymochko/status/1516920342400450562 13:56 - NFTs are investing in a brand. You can essentially buy a brand name, like buying Radio Shack. “The most valuable real estate is the corner of someone's mind” (John Hegarty quote)16:30 - Status games / signaling w/ NFTs18:22 - Summarizing the facets and layers of NFTs for entrepreneurs to be aware of. Networking benefits, status benefits, financial benefits, claims to airdrops, IP ownership, cooperation with other brands, and deal flow. None of this is new.20:45 - Moonbirds. What are they? What just happened?23:49 - NFT mint analogy to kickstarter; better when you already have an audience.25:14 - Subgroups within NFT clubs, and subgroups of subgroups25:35 - Jesse believes Quirkies is the strongest community in the NFT space. Examples of people helping each other out.27:00 - Importance of understanding basic cybersecurity when diving into the NFT space.27:10 - Recap of Moonbirds, why it seemed like a good investment (analysis from a VC perspective). Nesting. Problem of diluting the term “staking” https://cobie.substack.com/p/apecoin-and-the-death-of-staking 29:20 - How to teach entrepreneurs to use NFT clubs to help humans flourish32:53 - Two pieces of advice that Will got early in his startup investing career: 36:20 - Typical investment model, comparing NFTs to traditional investments…e.g. is the team “known”? Is there real traction or just “fake” traction? What's the roadmap?39:20 - 5 Part Matrix when evaluating an investment. Team, Product, Market, Traction, Financial Model, https://satchel.works/@wclittle/ventures-episode-62 40:10 - Don't silo your understanding in Web3. The multidisciplinary nature of DAOs, DeFi, Metaverses, NFTs, etc… 41:35 - APE Coin43:14 - Where can people get a hold of Jesse to continue the conversation? https://twitter.com/JesseBryan
Subgroup analyses in combination with data visualisation is one of the hottest topics I can think about. And it hits us as statisticians during our careers again and again. We need to understand subgroups for efficacy reasons and safety reasons and it's a common question in terms of how consistent your drug works across the different subgroups. It gets even more complicated if you want to review it across multiple studies.
Join Dr. Steve Gard, editor-and-chief for the Journal of Prosthetics and Orthotics, as he chats with Brian Kaluf about his research surrounding hydraulic- and microprocessor-controlled ankle-foot prostheses for limited community ambulators with unilateral transtibial amputation. The two discuss the experimental protocol of the research, data collection, primary findings, unanticipated surprises, and clinical takeaways. Show Notes JPO article: Hydraulic- and Microprocessor-Controlled Ankle-Foot Prostheses for Limited Community Ambulators with Unilateral Transtibial Amputation: Pilot Study Dr. Gard and Mr. Kaluf alludes to the body of evidence regarding microprocessor-controlled knees and transfemoral amputees with a K2 functional level classification. Here's the full article: The effect of microprocessor controlled exo-prosthetic knees on limited community ambulators: systematic review and meta-analysis (tandfonline.com) Mr. Kaluf mentions a previous study he conducted with a similar protocol with transtibial amputees in the K3 and K4 functional levels: Comparative Effectiveness of Microprocessor-Controlled and Carbon-Fiber Energy-Storing-and-Returning Prosthetic Feet in Persons with Unilateral Transtibial Amputation: Patient-Reported Outcome Measures Mr. Kaluf speaks about a systematic review that was published around the time of the design of the study described in the podcast. That review was performed by AHRQ and one of the aims was "comparison of component effects by subgroups": Lower Limb Prostheses: Measurement Instruments, Comparison of Component Effects by Subgroups, and Long-Term Outcomes | Effective Health Care (EHC) Program (ahrq.gov)
We discussed vegetables with Val Albright from Michigan State University Extension. See omnystudio.com/listener for privacy information.
We're back at it again this week and we're sharing our thoughts on the different subgroups we've noticed in the coaster community. Mineblower is the Coaster of the Week and Disney Parks are this week's Coaster College topic! Thank you to all of you listeners, you guys rock! Come check out the Cuzzie's discord at https://discord.gg/abTDb3eVav You can find the links to our show's socials at https://www.prairiecoasting.ca/ If you're interested in extra content and perks from us check out our Patreon at https://www.patreon.com/prairiecoasting or check out the store at https://www.teepublic.com/user/prairie-coasting-podcast all proceeds from the patreon and profits from the store are matched then donated to Prairie Harm Reduction (Safe Consumption site in Saskatoon). See you guys next week. Till then take care Eh!
In Today's episode, let's welcome our special guest Patrick Allen. Patrick Allen is a licensed real estate agent who moved to Tucson in 2013 from Nashville, TN. A former ultra-endurance triathlon coach, Patrick has a passion for helping home buyers and real estate investors alike accomplish their goals of buying their first, or next, property. Patrick enjoys serving his community through outreach programs surrounding investing and financial independence. In his free time, Patrick enjoys playing kickball, traveling, drinking craft beer and morning walks with his dog Artemis. Make sure to listen to the full episode as Patrick discusses finding deals, how newbies can get started, and the Tucson group curriculum. Whether you are an experienced investor with a large portfolio, or just getting started and looking to secure income and wealth through real estate investing the AZREIA Show is here for you. This podcast provides you with exceptional education, resources, and support to help you further your real estate career. Our community consists of independent real estate investors who utilize a myriad of investment strategies. If you're looking to learn from the most successful investors in the industry then you have found your new home. KEY TAKEAWAYS IN THIS EPISODE: 03: 14 Get to know Patrick Allen 06: 35 Real estate as a side hustle transition to full-time 07:47 The most straightforward ways to get started investing if you don't have a lot of capital. 13:13 Patrick provides service to the residents of Tucson 14:32 Patrick's primarily looking at Tucson market right now 15:49 Connect with Patrick 18:06 Benefits of being a member of Patrick's Subgroup in Tucson. 21:20 The beginning of Patrick's Subgroups in Tucson area (story revealed) 22:17 What is “Deal funnel at the top” 23:26 Newbie investors curriculum to learn real estate investing with Patrick (pretty polished) 27:42 Patrick's most intriguing part about being a Sub Group Leader. 28:49 Philosophy of “Why is this the next step?” 30:56 Characteristics that a newbie investor should have in order to reach the level of success. 34:13 Azreia Calendar of Events. Find out more about our guest at: https://www.biggerpockets.com/users/pat_allen Email: patrick@teamintegritytucson.com Phone: 520.275.7368 ----- Thanks for listening to the AZREIA SHOW Podcast with Marcus Maloney and Michael Del Prete. Don't forget to subscribe to the show on iTunes and leave a rating and review. See you on our next episode! To learn more about investing and to understand your investor identity to the free Entrepreneur Self Assessment at: https://azreia.org/entrepreneurial-self-assessment/ Azreia Real Estate Investing Entrepreneurial Self Assessment Who is if for? Anyone who wants to know if Real Estate Investing is right for them BEFORE spending time or money on education and training. Everyone new to Real Estate Investing Our Entrepreneurial Self Assessment is designed for you to understand if Real Estate Investing is right for you and if so, you are best suited for active or passive investing. Join our conversation at: Facebook: Twitter: Instagram: Website: LinkedIn:
GSA divides contractors up into different categories based on their Industry and Special Item Numbers, but did you know they break it down even further with subgroups? Subgroups are a self certified designation on your eBuy profile that can help Purchasing Officers get a better idea of the work that your company actually does. Find out more about subgroups and how to get them added to your profile in the episode!As always, if you have any questions, or requests for a future episode, please feel free to reach out to us at podcast@elevategsa.com. Or if you’d like direct support from a GSA consultant to help with a specific project, reach out to us at info@elevategsa.com.Episode Notes:For more episodes: www.elevategsa.com/podcasteBuy: www.ebuy.gsa.govThe following SINs have subgroups: 561210FA, 541690E, 332311P, 532490P, 333241, 336999, 333318F, 335999, 325612, 325998, 325611, 54151HACS, 517312, 54151S, 54151ECOM, 511210, 33411, 339940OS4, 541611, 562112, 541211, 522310, 541330ENG, 562910REM, 541930, 541614, 541620, 561621H, 339113LAB, 334515, 334516, 333997, 332439.
People Group Summary Sign up to receive podcast: https://joshuaproject.net/people_groups/15840/ET Listen to the "Gateway to the Unreached" with Greg Kelley, produced by the Alliance for the Unreached: https://alliancefortheunreached.org/podcast/ Watch "Stories of Courageous Christians" w/ Mark Kordic https://storiesofcourageouschristians.com/stories-of-courageous-christians God's Best to You!
Cutting Through the Matrix with Alan Watt Podcast (.xml Format)
--{ "By Lockdown, Planet Sustainable Becomes Obtainable: Tyrannical Oligarchs are Only Beginning To Implement Insanity Disguised as Winning A War to Save Us from a Deadly Disease Which We Mostly Defeat With Hardly a Sneeze, If it weren't for the Swab-on-a-Stick, Life Would Continue, No Need for The Prick Or the Tracking Apps for 5G Surveillance And Mask Suffocation to Prove our Obeyance To The Wizard-of-Laws Spewing Out Rules, Crafting the Normals into Hysterical Fools Sanity, Once Fresh, Logical, Turned to Curd, Terror-News T.V. is Theatre-of-the Absurd, Rights Won through Getting Up Off Our Knees Tossed Like Confetti, Masters to Please, Satisfying Psychopaths Hasn't a Chance, After Every Compliance they Again Advance To Their Brave New World for Deserving Few, Post Non-Essential, Post-Excess, Mostly-Post-You."© Alan Watt }-- Fairy Stories - Statistics - Handouts to Media; Raise Anxiety - Free Trade - Building Back Better - BLM, Antifa Burning and Looting - Silent Weapons for Quiet Wars - China - Bioweapons - A Managed Script, Changing Facts, No Continuity of Story - GM to Stop Producing Gas Vehicles by 2035 - Agenda 21, No Private Vehicles - Covid Passports - Communitarianism; Collectivism - Dachas for Elite Civil Servant Class - Neil Ferguson, Computer Models, Authoritarian Rule - The Meaning of Life - Visit My Website, www.cuttingthroughthematrix.com and Please Donate - Counterintelligence - Cultural Changes, Old Movies; Separating the Generations, Creation of Subgroups, Subcultures in Society - Family, Common Costume, Language, Cooperation - Hollywood, Young Rebel Movies - Teddy Boys, Beatniks; Lingo, Squares - Movie, Beat Girl; Adam Faith; British Copied American Youth Culture - Desolation, Purposelessness - Psychological Warfare Under the Guise of Entertainment - Discourage Bonding and Breeding - Marxism; Destroy Decent Painting; Atonal Music - Bob Dylan - Hallucinogenic Drugs - Seattle, Tent Cities; 2008 Financial Crash, Flooded with Drugs; Legalizing Marijuana - Documentary, Oxyana - Psychological Experiments, Disco, Strobe Lights; Unabomber - Rave Parties, Psychoactive Drugs - Hypnosis, MK ULTRA, Psychic Driving, CIA - Britain's Deindustrialization; Manufacturing Moved to China - UBI - Covid, Emergency Powers, Martial Law - Utopia - U.S. will Sink into Barbarism when It has Served its Purpose - Empires - Syria and Iran - U.S. Capitol, January 6, 2021, Perception Management - Genocide Starts with Name-Calling, Dehumanizing - The Elite Despise the Military - The Great Reset; Climate Change and Covid to Usher in Big Changes - Public-Private Partnerships - WEF; 5G, Internet of Things; Complete Surveillance - Xi at Virtual Davos Forum - Global Research eBook, The 2020 Worldwide Corona Crisis: Destroying Civil Society, Engineered Economic Depression, Global Coup d'État and the “Great Reset” - Corman-Drosten Review Report - A Brief Examination of Some Facts Related to Mass Vaccination, by Gilad Atzmon - Genocide, Censorship - Sen. Ron Johnson, YouTube Removed Two Videos from a Senate Hearing about COVID-19 Treatments - Macron Questions Vaccine Credibility as EU Approves AstraZeneca Jab - Bioethics - Italian COVID Doctor Charged with Killing Weak to Save Strong - West Midlands Police Apologise - Facebook Tool to Help Advertisers Avoid Bad News - Paul Craig Roberts, Demonization of Russia, China, and Iran - Article, Why does US Central Command Now Include Israel? - Proud Boys Leader was ‘prolific' Informer for Law Enforcement - FBI Stings - Counterintelligence - Dutch Curfew Riots - Vaccinated Brits Could Still Spread Covid - Californian Dies Hours after Receiving COVID Vaccine - China's Zero-Tolerance Covid Tactics Now Include Anal Swabs - Movie, Equilibrium - Movie, Eyeborgs - Much of What You See Might Not Be Real at All - Thinking for Yourself - Blair Pushes for G7 to Back Global Covid Vaccine Passport Scheme - FAA Approves Commercial Drones to Fly Over People - Movie, Utopia with Laurel and Hardy - FEMA Asks DOD for Help Administering COVID-19 Vaccines - Help Each Other Out. *Title and Dialogue Copyrighted Alan Watt - Jan. 31, 2021 (Exempting Music and Literary Quotes)
Gary takes on the real issues that the mainstream media is afraid to tackle. Tune in to find out the latest about health news, healing, politics, and the economy. Meta-analysis finds dietary supplements improve sleep quality Hong Kong Polytechnic University, January 27 2021. A systematic review and meta-analysis published on January 13, 2021 in Postgraduate Medical Journal found benefits for supplemental vitamin D, melatonin and amino acids in improving the quality of sleep among men and women. The meta-analysis included 15 randomized, controlled trials that examined the association between subjective sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) and supplementation with amino acids, the hormone melatonin, omega 3 fatty acids and vitamin D. Pooled data for the two studies involving amino acid supplements, seven studies involving melatonin, and four studies involving vitamin D each showed significant differences between supplemented and control groups, with more favorable PSQI scores occurring among those who received the supplements. The two studies that evaluated omega 3 did not reveal significant differences between the treatment and control groups. Two reviewed trials that were not eligible for inclusion in the meta-analysis added evidence to the benefit of melatonin in sleep quality. Other non-included trials found a benefit for nitrate-containing beetroot juice, resveratrol and zinc supplements. Co-supplementation with melatonin, magnesium and zinc was also associated with a significant benefit in comparison with a placebo. “Although we found a significant improvement in sleep quality by dietary supplementation, randomized, controlled trials with longer duration and larger sample size should be conducted to verify our findings,” noted authors Vicky Chan and Kenneth Lo of The Hong Kong Polytechnic University. “Furthermore, dose–response effect of different supplements on sleep quality has not yet been evaluated.” “Amino acids, vitamin D and melatonin supplements were significantly beneficial to improve sleep quality,” they concluded. “Further research on the effect of magnesium, zinc, resveratrol and nitrate supplementation on improving sleep quality is required.” Green coffee extract and silymarin protect against carbon tetrachloride-induced liver toxicity University of Tabuk (Saudi Arabia), January 26, 2021 According to news originating from the University of Tabuk research stated, “During the last few decades, patients worldwide have been interested in using alternative medicine in treating diseases to avoid the increased side effects of chemical medications. Green coffee is unroasted coffee seeds that have higher amounts of chlorogenic acid compared to roasted coffee.” Our news journalists obtained a quote from the research from University of Tabuk: “Green coffee was successfully used to protect against obesity, Alzheimer disease, high blood pressure and bacterial infection. This study aimed to investigate the probable protective activity of the green coffee methanolic extract, silymarin and their combination on CCl4-induced liver toxicity in male rats. Thirty Sprague - Dawley male albino rats were divided into 5 groups; control negative (G1) just got the vehicle (olive oil) and the other four groups received CCl4 dissolved in olive oil through an intraperitoneal injection and were divided into untreated control positive group (G2), the third group (G3) was treated with green coffee methanolic extract, the fourth group (G4) was treated with silymarin, and the fifth group (G5) was treated with a combination of green coffee methanolic extract and silymarin. In the positive control group treated with CCl4 (G2), the CCl4-induced toxicity increased lipid peroxidation, IL-6, kidney function parameters, liver function enzymes, total cholesterol, triglycerides and low-density lipoproteins, and decreased irisin, antioxidants, CYP450 and high-density lipoprotein levels. Hepatic tissues were also injured. However, treating the injured rats in G3, G4 and G5 significantly improved the altered parameters and hepatic tissues.” According to the news reporters, the research concluded: “Green coffee methanolic extract, silymarin, and their combination succeeded in protecting the male rats against CCl4 hepatotoxicity due to their antioxidant activity. Effect of green coffee methanolic extract mixed with silymarin in G5 was more efficient than that of green coffee methanolic extract in G3 or silymarin in G4.” Vitamin D status and outcomes for hospitalised older patients with COVID-19 NHS Foundation Trust and University of Cyprus, January 21, 2021 Purpose Older adults are more likely to be vitamin D deficient. The aim of the study was to determine whether these patients have worse outcomes with COVID-19. Methods We conducted a prospective cohort study between 1 March and 30 April 2020 to assess the importance of vitamin D deficiency in older patients with COVID-19. The cohort consisted of patients aged ≥65 years presenting with symptoms consistent with COVID-19 (n=105). All patients were tested for serum 25-hydroxyvitamin D (25(OH)D) levels during acute illness. Diagnosis of COVID-19 was confirmed via viral reverse transcriptase PCR swab or supporting radiological evidence. COVID-19-positive arm (n=70) was sub-divided into vitamin D-deficient (≤30 nmol/L) (n=39) and -replete groups (n=35). Subgroups were assessed for disease severity using biochemical, radiological and clinical markers. Primary outcome was in-hospital mortality. Secondary outcomes were laboratory features of cytokine storm, thoracic imaging changes and requirement of non-invasive ventilation (NIV). Results COVID-19-positive arm demonstrated lower median serum 25(OH)D level of 27 nmol/L (IQR=20–47 nmol/L) compared with COVID-19-negative arm, with median level of 52 nmol/L (IQR=31.5–71.5 nmol/L) (p value=0.0008). Among patients with vitamin D deficiency, there was higher peak D-dimer level (1914.00 μgFEU/L vs 1268.00 μgFEU/L) (p=0.034) and higher incidence of NIV support and high dependency unit admission (30.77% vs 9.68%) (p=0.042). No increased mortality was observed between groups. Conclusion Older adults with vitamin D deficiency and COVID-19 may demonstrate worse morbidity outcomes. Vitamin D status may be a useful prognosticator. Mental Disorders Forecast Chronic Physical Diseases, Premature Death University of Michigan, January 22, 2021 Poor early-life mental health may jeopardize later-life physical health, according to a new study led by a University of Michigan researcher. The study, published in the journal JAMA Network Open, indicates that people who experience psychiatric conditions when they are young are likely to experience excess age-related physical diseases when they are older. Leah Richmond-Rakerd, U-M assistant professor of psychology, and colleagues found that this association cannot be explained by preexisting physical illness; they ruled out the possibility of reverse causation in which having a physical illness precipitates mental health problems. Prior studies had not taken this into account. This association is present across different mental disorders and different physical diseases, she said. The researchers conducted a nationwide hospital-register study of 2.3 million New Zealanders—aged 10-60 years at baseline—followed across three decades (1988 to 2018). They tested whether individuals with mental disorders are at increased risk for subsequent chronic physical diseases and premature mortality. Richmond-Rakerd and colleagues collected information about hospital admissions for different mental disorders, such as substance use disorders, psychotic disorders, mood disorders, anxiety disorders and self-harm behavior. In addition, researchers collected information about hospital admissions for different chronic physical diseases, ranging from coronary heart disease to cancer. Across the 30-year period, individuals with mental disorders were more likely to develop subsequent physical diseases and they also died earlier than people without mental disorders, the study showed. They also experienced more medical hospitalizations, spent more time in hospitals for physical-disease treatment and accumulated more associated health care costs. These associations were present across all age groups and in both men and women. The findings indicate that addressing mental health problems in early life might be a window of opportunity for preventing future physical diseases, Richmond-Rakerd said. They also suggest the importance of joined-up services, or integrated care. “Our health care system often divides treatment between the brain and the body,” she said. “Integrating the two could benefit population health.” Richmond-Rakerd said they chose New Zealand because there it is possible to link hospital registers and other administrative databases for the entire population of the country. The study’s co-authors are Stephanie D’Souza and Barry Milne of the University of Auckland, Avshalom Caspi and Terrie Moffitt of Duke University and King’s College London. 'Aging well' greatly affected by hopes and fears for later life, study finds Oregon State University, January 21, 2021 If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows. "How we think about who we're going to be in old age is very predictive of exactly how we will be," said Shelbie Turner, a doctoral student in OSU's College of Public Health and Human Sciences and co-author on the study. Previous studies on aging have found that how people thought about themselves at age 50 predicted a wide range of future health outcomes up to 40 years later -- cardiovascular events, memory, balance, will to live, hospitalizations; even mortality. "Previous research has shown that people who have positive views of aging at 50 live 7.5 years longer, on average, than people who don't," said Karen Hooker, co-author of the study and the Jo Anne Leonard Petersen Endowed Chair in Gerontology and Family Studies at OSU. Because self-perceptions of aging are linked to so many major health outcomes, Hooker and Turner wanted to understand what influences those perceptions. Their study looked specifically at the influence of two factors: self-efficacy associated with possible selves, meaning a person's perceived ability to become the person they want to be in the future; and optimism as a general personality trait. The researchers measured self-perception of aging by having respondents say how strongly they agreed or disagreed with statements such as, "Things keep getting worse as I get older," "I have as much pep as I had last year," "As you get older, you are less useful." They measured optimism in a similar way, with respondents ranking their agreement with statements like "In uncertain times I usually expect the best." To measure self-efficacy, the study used a dataset that compiled survey responses from older adults where they listed two "hoped-for" future selves and two "feared" future selves, and ranked how capable they felt of becoming the person they hoped to be and avoiding becoming the person they feared to be. Among the "hoped for" selves were things like "A social person with a strong network of friends" and "A healthy, active person." Examples of "feared" selves were "Chronically sick and in pain," "Being dependent on others for my day-to-day needs" and "A cranky, angry old woman." Results showed that, as predicted, higher optimism was associated with more positive self-perception of aging. Both "hoped-for" self-efficacy and "feared" self-efficacy were also significantly associated with self-perception of aging, above and beyond optimism as a trait. A major factor in how people see their own aging selves is internalizing ageist stereotypes, the researchers said. Examples of such stereotypes include assumptions that older adults are bad drivers, or suffer memory problems, or are unable to engage in physical activity anymore. "Kids as young as 4 years old already have negative stereotypes about old people," Hooker said. "Then, of course, if you're lucky enough to live to old age, they eventually apply to you." Those stereotypes get reinforced every time an older adult forgets something and jokes, "Another senior moment!" But the researchers say these thought patterns can do real harm. "People need to realize that some of the negative health consequences in later life might not be biologically driven. The mind and the body are all interwoven," Hooker said. "If you believe these bad things are going to happen, over time that can erode people's willingness or maybe even eventually their ability to engage in those health behaviors that are going to keep them as healthy as they can be." A way to mitigate those negative stereotypes about aging is to promote intergenerational relationships, so younger people can see older adults enjoying happy, healthy lives. "The more you're around older people, the more you realize that it's not all bad," Turner said. "Older people can do some things better than young people do. Increasing opportunities for intergenerational relationships is one way we can make people more optimistic about aging." Over half of cannabis users with Parkinson's disease report clinical benefits University Medical Center Hamburg-Eppendorf (Germany), January 26, 2021 With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson's disease (PD). According to results of a survey of PD patients in Germany in the Journal of Parkinson's Disease, over 8% of patients with PD reported using cannabis products and more than half of those users (54%) reported a beneficial clinical effect. Cannabis products containing THC (tetrahydrocannabinol, the main psychoactive compound of cannabis) can be prescribed in Germany when previous therapies are unsuccessful or not tolerated, and where cannabis can be expected with not a very unlikely chance to relieve disabling symptoms. CBD (pure cannabidiol, derived directly from the hemp plant, a cousin of the marijuana plant) is available without a prescription from pharmacies and on the internet. "Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data," explained lead investigator Prof. Dr. med. Carsten Buhmann, Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. "PD patients fulfilling these criteria are entitled to be prescribed medical cannabis, but there are few data about which type of cannabinoid and which route of administration might be promising for which PD patient and which symptoms. We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result." Investigators aimed to assess patient perceptions of medicinal cannabis as well as evaluate the experiences of patients already using cannabis products. They performed a nationwide, cross-sectional, questionnaire-based survey among members of the German Parkinson Association (Deutsche Parkinson Vereinigung e.V.), which is the largest consortium of PD patients in German-speaking countries with nearly 21,000 members. Questionnaires were sent out in April 2019 with the association's membership journal and were also distributed in the investigators' clinic. Over 1,300 questionnaires were analyzed; results showed that interest in the PD community in medical cannabis was high, but knowledge about different types of products was limited. Fifty-one percent of respondents were aware of the legality of medicinal cannabis, and 28% were aware of the various routes of administration (inhaling versus oral administration), but only 9% were aware of the difference between THC and CBD. More than 8% of patients were already using cannabinoids and more than half of these users (54%) reported that it had a beneficial clinical effect. The overall tolerability was good. Over 40% of users reported that it helped manage pain and muscle cramps, and more than 20% of users reported a reduction of stiffness (akinesia), freezing, tremor, depression, anxiety, and restless legs. Patients reported that inhaled cannabis products containing THC were more efficient in treating stiffness than oral products containing CBD but were slightly less well tolerated. Patients using cannabis tended to be younger, living in large cities, and more aware of the legal and clinical aspects of medicinal cannabis. Sixty-five percent of non-users were interested in using medicinal cannabis, but lack of knowledge and fear of side effects were reported as main reasons for not trying it. "Our data confirm that PD patients have a high interest in treatment with medicinal cannabis but lacked knowledge about how to take it and especially the differences between the two main cannabinoids, THC and CBD," noted Prof. Dr. med. Buhmann. "Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. The data reported here may help physicians decide which patients could benefit, which symptoms could be addressed, and which type of cannabinoid and route of administration might be suitable." "Cannabis intake might be related to a placebo effect because of high patient expectations and conditioning, but even that can be considered as a therapeutic effect. It has to be stressed, though, that our findings are based on subjective patient reports and that clinically appropriate studies are urgently needed," he concluded. Bastiaan R. Bloem, MD, PhD, Director, Radboudumc Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands, and Co-Editor-in Chief of the Journal of Parkinson's Disease, added: "These findings are interesting in that they confirm a widespread interest among patients in the use of cannabis as a potential treatment for people living with PD. It is important to emphasize that more research is needed before cannabis can be prescribed as a treatment, and that guidelines currently recommend against the use of cannabis, even as self-medication, because the efficacy is not well established, and because there are safety concerns (adverse effects include among others sedation and hallucinations). As such, the present paper mainly serves to emphasize the need for carefully controlled clinical trials to further establish both the efficacy and safety of cannabis treatment." Covid lockdown loneliness linked to more depressive symptoms in older adults University of Exeter (UK), January 22, 2021 Loneliness in adults aged 50 and over during the COVID-19 lockdown was linked to worsening depressive and other mental health symptoms, according to a large-scale online study. Loneliness emerged as a key factor linked to worsening symptoms of depression and anxiety in a study of more than 3,000 people aged 50 or over led by the University of Exeter and King's College London, and funded by The National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC) . Researchers had access to data going back to 2015 for participants of the PROTECT online study. They also found that a decrease in physical activity since the start of the pandemic was associated with worsening symptoms of depression and anxiety during the pandemic. Other factors included being female and being retired. Dr Byron Creese, of the University of Exeter Medical School, who led the study, said: "Even before the pandemic, loneliness and physical activity levels were a huge issue in society, particularly among older people. Our study enabled us to compare mental health symptoms before and after COVID-19 in a large group of people aged 50 and over. We found that during lockdown, loneliness and decreased physical activity were associated with more symptoms of poor mental health, especially depression. It's now crucial that we build on this data to find new ways to mitigate risk of worsening mental health during the pandemic." The study found that before the pandemic, lonely people would report an average of two symptoms of depression for at least several days over the previous last two weeks. During lockdown, lonely people reported either an increase in frequency of depressive symptoms, to more than half the days in the two week period, or a new symptom for at least several days in that timeframe. In people who were not lonely, levels of depressive symptoms were unaffected. PROTECT began in 2011, and has 25,000 participants signed up. Designed to understand the factors involved in healthy ageing, the innovative study combines detailed lifestyle questionnaires with cognitive tests that assess aspects of brain function including memory, judgment and reasoning over time. In May, researchers included a new questionnaire designed to assess the impact of COVID-19 on health and wellbeing. Running from May 13 to June 8, the questionnaire was completed by 3,300 people, of which 1,900 were long-standing PROTECT participants. The study is continuing to run so that longer term outcomes can be assessed. Zunera Khan, Research Portfolio Lead at Institute of Psychiatry, Psychology & Neuroscience said "We've found links between loneliness and a drop in physical exercise and worsening mental health symptoms. It should be within our power to find ways of keeping people socially engaged and active. Our online PROTECT platform ultimately aims to find new ways to engage people in their homes, however, technology can only be part of the picture. We need to ensure we can find new ways to help people stay active and social, whether they are online or not." Professor Clive Ballard, Executive Dean and Pro-Vice Chancellor of the University of Exeter Medical School, who leads PROTECT, said: "We are only just beginning to learn the impact that COVID-19 is having on the health and wellbeing of older people. For example, the effect of any economic impact may not yet have emerged. Our large scale study will span a number of years, and will help us understand some of the longer-term effects of COVID-19 on mental health and wellbeing, and ultimately, on whether this has any knock-on effect on aspects of ageing, such as brain function and memory. " The study plans to conduct further analysis on groups at particularly high risk, such as people with cognitive impairment and those with caring rolesG
Are you a school or district leader who believes that you can become a change agent in your district? Listen to hear how one district leader organized meetings and subgroups to tackle a change effort in her district. Be the change that you want to see in the world!
Today on AirTalk, we discuss the latest Loyola Law School report focusing on deputy policing. Also on the show, we update you on the latest COVID-19 news and answer your questions; hear from listeners about the lies they have told during interviews; and more.
In this episode, Joel and Antonia talk with guest host Dr. Dario Nardi about the subgroups that have emerged around studying Myers-Briggs personality types. https://personalityhacker.com
An analysis of four molecular datasets shows a distinct signature, including changes in gene expression and chemical DNA modifications, in some autism brains. The post Integrating molecular data may reveal subgroups of autism appeared first on Spectrum | Autism Research News.
An analysis of four molecular datasets shows a distinct signature, including changes in gene expression and chemical DNA modifications, in some autism brains.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.06.239152v1?rss=1 Authors: Rahaman, M. A., Damaraju, E., Turner, J., van Erp, T. G. M., Mathalon, D., Vaidya, J., Muller, B., Pearlson, G. D., Calhoun, V. D. Abstract: Background: Brain imaging data collected from individuals are highly complex with unique variation; however, such variation is typically ignored in approaches that focus on group averages or even supervised prediction. State-of-the-art methods for analyzing dynamic functional network connectivity (dFNC) subdivide the entire time course into several (possibly overlapping) connectivity states (i.e., sliding window clusters). Though, such an approach does not factor in the homogeneity of underlying data and may end up with a less meaningful subgrouping of the dataset. Methods: Dynamic-N-way tri-clustering (dNTiC) incorporates a homogeneity benchmark to approximate clusters that provide a more apples-to-apples comparison between groups within analogous subsets of time-space and subjects. dNTiC sorts the dFNC states by maximizing similarity across individuals and minimizing variance among the pairs of components within a state. Results: Resulting tri-clusters show significant differences between schizophrenia (SZ) and healthy control (HC) in distinct brain regions. Compared to HC, SZ in most tri-clusters show hypoconnectivity (low positive) among subcortical, default mode, cognitive control but hyper-connectivity (high positive) between sensory networks. In tri-cluster 3, HC subjects show significantly stronger connectivity among sensory networks and anticorrelation between subcortical and sensory networks compared to SZ. Results also provide statistically significant difference in reoccurrence time between SZ and HC subjects for two distinct dFNC states. Conclusions: Outcomes emphasize the utility of the proposed method for characterizing and leveraging variance within high-dimensional data to enhance the interpretability and sensitivity of measurements in the study of a heterogeneous disorder like schizophrenia and in unconstrained experimental conditions such as resting fMRI. Copy rights belong to original authors. Visit the link for more info
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.04.235762v1?rss=1 Authors: Groot, C., Grothe, M. J., Mukherjee, S., Jelistratova, I., Jansen, I., van Loenhoud, A. C., Risacher, S. L., Saykin, A. J., Mac Donald, C. L., Mez, J., Trittschuh, E. H., Gryglewski, G., Lanzenberger, R., Pijnenburg, Y. A. L., Barkhof, F., Scheltens, P., van der Flier, W. M., Crane, P. K., Ossenkoppele, R. Abstract: Elucidating mechanisms underlying the clinical heterogeneity observed among individuals with Alzheimer's disease (AD) is key to facilitate personalized treatments. We categorized 679 individuals with AD into subgroups based on a relative impairment in one cognitive domain (i.e. AD-Memory, AD-Executive-Functioning, AD-Language and AD-Visuospatial-Functioning). We compared atrophy patterns derived from MRI and identified patterns that closely matched the respective cognitive profiles, i.e. medial temporal lobe atrophy in AD-Memory, fronto-parietal in AD-Executive-Functioning, asymmetric left-temporal in AD-Language, and posterior in AD-Visuospatial-Functioning. We then determined spatial correlations between subgroup-specific atrophy and a transcriptomic atlas of gene expression, which revealed both shared (e.g. mitochondrial respiration and synaptic function/plasticity) and subgroup-specific (e.g. cell-cycle for AD-Memory, protein metabolism in AD-Language, and modification of gene expression in AD-Visuospatial-Functioning) biological pathways associated with each subgroup's atrophy patterns. We conclude that cognitive heterogeneity in AD is related to neuroanatomical differences, and specific biological pathways may be involved in their emergence. Copy rights belong to original authors. Visit the link for more info
In the first episode of Avalere's Journal Club Review, our experts discuss the findings, themes, and relevant application of a contemporary healthcare publication.
People Group Summary https://joshuaproject.net/people_groups/15234 Listen to the "Gateway to the Unreached" with Greg Kelley, produced by the Alliance for the Unreached: https://alliancefortheunreached.org/podcast/
In this episode of Diabetes Insights with Dr. Brian Mowll, we discuss a 2018 paper from the Lancet Journal about five novel subgroups types of diabetes. Dr. Mowll explains the main findings of this study including a detailed description of each of the subgroups and how it relates to people with diabetes. He also gives his commentary about the most useful clinical insights from the research report. Diabetes Insights is a solo format podcast with Dr. Brian Mowll exploring the latest and most interesting research in the field of diabetes, blood sugar, and metabolic health, and distilling the most relevant data for clinical use. This special podcast episode is geared toward healthcare professionals and those with an interest in learning more about diabetes and the latest advancements in understanding and treatment. Subscribe to the Mastering Blood Sugar podcast to get updates when new episodes are released.
Brian talks with Vickie Perry about the different Subgroups that CIREIA offers. They have you covered!
Brian talks with Vickie Perry about the different Subgroups that CIREIA offers. They have you covered!
In this episode, we discuss subgroups with Andrew LaValley of Bear Sound. Original music for this podcast is provided by Joshua Stromer https://www.joshuastromermusic.com/Other Links:Free multitrack sessions for mixing practice http://www.cambridge-mt.com/ms/mtk/Cool and helpful audio accessories http://soundtools.com/Fundamental frequencies https://www.teachmeaudio.com/recording/sound-reproduction/fundamental-harmonic-frequencies/Link to Bob McCarthy's website: https://bobmccarthy.com/http://www.madbearsound.com/
People Group Summary: https://joshuaproject.net/people_groups/19978 Listen to the "Gateway to the Unreached" with Greg Kelley, produced by the Alliance for the Unreached: https://alliancefortheunreached.org/podcast/
we have all been there, right? teams get headed in all kinds of directions. i believe the intentionality we put behind how we talk about things is what takes teams from good to GREAT. Check out more on the death of a dream and for opportunities to work one on one with the host, be a guest on the podcast or be featured check out: www.nussinc.com
Imposter Syndrome: What is it and how to rise above it! Imposter Syndrome and You - Do you struggle with any of the 5 Subgroups of Imposter Syndrome? Tune in as host Jill Fleming shares her research of personal knowledge of Imposter Syndrome and also shares the 5 Sub-Groups of Imposter Syndrome according to according to Dr. Valerie Young in her book, The Secret Thoughts of Successful Women: Why Capable People Suffer From the Imposter Syndrome and How to Thrive in Spite of It. Are you dealing with imposter syndrome? Are you're feeling stuck and stagnant and are READY to make a transition or change, but are unsure of where to start and would like a "Wing Woman" to guide you on your transformation journey? If so, schedule your free one-to-one 30-minute consultation with Jill at www.schedulejill.com Sponsored by: Jill Fleming’s Best Selling Book – Freedom to Fly: The Visionary Leader’s Guide to Unlocking Your Unique Freedom Code to Confidently Create More Impact, Influence & Income – Get Your Copy today at http://bit.ly/freedomtoflybook Music courtesy of Daniel Hoshor - AwakenedYouth.co ============================================================== Disclaimers The content on Time2Fly Podcast is for informational purposes only and is not intended to replace consultation with a qualified business professional. None of it should it be construed as business advice. Consult with a qualified business professional (i.e. CPA, Lawyer, Tax Accountant) with any questions you may have regarding any questions you may have about information provided on the show. The views expressed by the co-hosts and the guests are opinions and/or interpretations of their experiences or information obtained through outside sources and are shared in good faith and with the belief that they may help lead to improved business results. The co-hosts and their affiliated businesses do not accept any responsibility for any damages real or perceived and shall not be liable or responsible for any loss or damage allegedly arising from any information or suggestions within. You are 100% responsible for your personal and business decisions. Testimonials and examples used are exceptional results and are not intended to guarantee, promise, represent and/or assure that anyone will achieve the same or similar results... they are shared merely to show what is possible. Your results may vary. By signing up for any of our consulting or coaching programs, you are only paying for motivation, access to our supportive community and our curated list of resources. Most of the information and suggestions are provided as a courtesy and are available in various places online often free of charge. This service is provided as a convenience, to save you time, and to keep you motivated.
Commentary by Dr. Valentin Fuster
Topics: Mr oH’s book launch, Mums vs wives, Toxicity, Subgroups, Do road boys have a shelf life?, Spac nation & much much more... Host: Rhys Waul - Twitter: @Raw_Like_Me - Instagram: Rawlikeme, Mark Brown - Twitter: @Mister2Drink - Instagram: Mister2Drink - MrOh - Twitter: @MrOhYes - Instagram: Misterohhhhh
In this episode, our first episode. We introduce ourselves - Rhonda Solis and Chris Garcia, and take a second to introduce subgroups who make up the Latina/o/x community in Northern Colorado.
Drs. Jack West & Alex Drilon, from Memorial Sloan-Kettering, discuss opportunities & challenges of studying narrow molecularly-defined patient subgroups, (MET, RET, TRK, & others), along with the increasingly active role of online patient groups.
Drs. Jack West & Alex Drilon, from Memorial Sloan-Kettering, discuss opportunities & challenges of studying narrow molecularly-defined patient subgroups, (MET, RET, TRK, & others), along with the increasingly active role of online patient groups.
Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. This month we review articles on: Cardiovascular Risk Factor Burden in Patients with Diabetes Identification of Subgroups that Benefit Most In Diabetes Prevention Program Metformin and Type 2 Diabetes Prevention Detection of Hypoglycemia Using Heart Rate Variability on a Wearable Device Effect of Glucose Improvement on Pulmonary Function in Patients with Diabetes Improving Adherence to Metformin Therapy For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Abington Jefferson Health
ICSW Ep9 Dives into my Mexican Vacation, the Holidays, and #ICCC2018. With special guest star Kris Santin talking all about The Subgroups of The Imperial Commissary! -IC
How to Search for Schools Experiencing Success with Subgroups that are Underperforming at Your School
I know my treatment doesn't work across a large population but what about subgroups?! Ah yes. Subgroups. Subgroups are absolutely a thing but how do we go about defining them? Do we just track everyone we treat then look back to see who responded and who didn't? Or is it more complicated than that? Find out on this dynamite episode of Nobel proportions! Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials. Wallach JD, Sullivan PG, Trepanowski JF, Sainani KL, Steyerberg EW, Ioannidis JP. JAMA Intern Med. 2017 Feb 13. doi: 10.1001/jamainternmed.2016.9125. [Epub ahead of print] Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. That said, if you are having difficulty obtaining an article, contact us. Music for PT Inquest: "The Science of Selling Yourself Short" by Less Than Jake Used by Permission
Guest: Luc Martin My research interests lie in the general area of sport psychology with a particular focus on group dynamics principles. More specifically, I am interested in the psychosocial influences present in sport and physical activity settings, and how individuals’ can be influenced by, but can also influence the groups to which they belong. My current projects involve the investigation of group processes such as cohesion, cliques, social identity, and leadership on both individual and team level outcomes in child/youth and elite sport populations. Generally, the main focus is to develop a better understanding of certain psychosocial factors that can be used to inform interdisciplinary and policy relevant research aimed at enriching the sporting environment. Links: Email: luc.martin@queensu.ca Telephone: 613-533-6000 x79140 Website: http://www.queensu.ca/skhs/faculty-and-staff/faculty/luc-martin Additional link: Martin, L. J., Eys, M. A., & Spink, K. S. (2016). The social environment in sport organizations. In C. Wagstaff (Ed.), The Organizational Psychology of Sport: Key Issues and Practical Applications. Abingdon, UK: Routlege. http://journals.humankinetics.com/doi/abs/10.1123/tsp.2014-0003?journalCode=tsp
Interview with Fatima Rodriguez, MD, MPH, author of Disaggregation of Cause-Specific Cardiovascular Disease Mortality Among Hispanic Subgroups
Ariana Grande is a dangerous woman, and James can't stop raving about it. Game of Thrones has sent Nnekay to the crazy house. NO spoilers! James is finally drinking that Lemonade and getting in Formation- we break down the Beyonce debate as bell hooks and brilliant transgender activist and writer Janet Mock duke it out on the twitters. Did Nnekay's award winning journalism and reporting from last week help bring about the resigning of SF police chief? Also, it's the first ever Minority Korner sex tips! We're giving you a list of things that would epically suck if you do these things in bed! Or wherever you choose to rub your sexy parts on to each other. James is giving the Gay State of Affairs Union Address: Transphobia/Transpanic, bathrooms, murders, Walmart, and Bears oh my! James also breaks down gay male subgroups for Nnekay. If Nnekay where a gay man where would she fit? Will SF lose it's Pride festival this year? Is George Zimmerman still an asshole? Is Whitney Houston coming back in Hologram- find out in Quizlet Korner! http://feministing.com/2016/05/03/things-that-are-sexually-ethically-weird/
Dr. Nitin Seam talks with Drs. Ulrich Costabel and Athol Wells about idiopathic pulmonary fibrosis and which patients may benefit from nintedanib treatment. They discuss the INPULSIS trials and Dr. Costabel's article in the January 15 issue of AJRCCM.
Commentary by Dr. Valentin Fuster
Mathematical, Foundational and Computational Aspects of the Higher Infinite
Agarwal, L (University of Leeds) Friday 9th October 2015 - 15:50 to 16:45
Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.
Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.
Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.
Subgroups are powerful mixing and organising tools. Find out how to use them in this video.
Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.
Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.
Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.
Dr Thierry André talks to ecancertv at the ESMO 14th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona. As a medical oncologist with an interest in gastrointestinal cancer, Dr André gives his perspective on some of the important topics being discussed at the meeting. Specifically he mentions the use of new drugs for the management of patients with metastatic colorectal cancer (mCRC). Dr André also talks about the TML study that looked at the continuation of bevacizumab in the second line setting, commenting on results from new subgroup analyses presented at the WCGC. This programme was supported by BAYER.
Cheltsov, I (Edinburgh) Tuesday 24 May 2011, 15:30-16:30
Kenny Goldberg interviews Abby C. King, PhD regarding her article "Identifying Subgroups of U.S. Adults at Risk for Prolonged Television Viewing to Inform Program Development" appearing in the January 2010 Issue
© 2020-2025 Ivy Podcast Discovery LLC
